» Articles » PMID: 22260413

Cholesterol and the Risk of Grade-specific Prostate Cancer Incidence: Evidence from Two Large Prospective Cohort Studies with Up to 37 Years' Follow Up

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2012 Jan 21
PMID 22260413
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

Background: High cholesterol may be a modifiable risk factor for prostate cancer but results have been inconsistent and subject to potential "reverse causality" where undetected disease modifies cholesterol prior to diagnosis.

Methods: We conducted a prospective cohort study of 12,926 men who were enrolled in the Midspan studies between 1970 and 1976 and followed up to 31st December 2007. We used Cox-Proportional Hazards Models to evaluate the association between baseline plasma cholesterol and Gleason grade-specific prostate cancer incidence. We excluded cancers detected within at least 5 years of cholesterol assay.

Results: 650 men developed prostate cancer in up to 37 years' follow-up. Baseline plasma cholesterol was positively associated with hazard of high grade (Gleason score≥8) prostate cancer incidence (n = 119). The association was greatest among men in the 2nd highest quintile for cholesterol, 6.1 to < 6.69 mmol/l, Hazard Ratio 2.28, 95% CI 1.27 to 4.10, compared with the baseline of < 5.05 mmol/l. This association remained significant after adjustment for body mass index, smoking and socioeconomic status.

Conclusions: Men with higher cholesterol are at greater risk of developing high-grade prostate cancer but not overall risk of prostate cancer. Interventions to minimise metabolic risk factors may have a role in reducing incidence of aggressive prostate cancer.

Citing Articles

Nuclear magnetic resonance-based metabolomics and risk of pancreatic cancer: a prospective analysis in the UK Biobank.

Wu Z, Yang J, Ma Z, Chen Y, Han M, Wu Q J Gastroenterol. 2025; .

PMID: 40074913 DOI: 10.1007/s00535-025-02237-9.


Squalene monooxygenase (SQLE) protects ovarian cancer cells from ferroptosis.

Zhang R, Zhang L, Fan S, Wang L, Wang B, Wang L Sci Rep. 2024; 14(1):22646.

PMID: 39349544 PMC: 11442994. DOI: 10.1038/s41598-024-72506-9.


Cholesterol Metabolism and Urinary System Tumors.

Yang S, Ye Z, Ning J, Wang P, Zhou X, Li W Biomedicines. 2024; 12(8).

PMID: 39200296 PMC: 11351655. DOI: 10.3390/biomedicines12081832.


Investigating the Relationship between Body Mass Index, Cholesterol, and Cancer in United States Adults: A Cross-Sectional Study.

Martinovic A, Axon D Diseases. 2024; 12(6).

PMID: 38920552 PMC: 11202576. DOI: 10.3390/diseases12060120.


Cholesterol Dietary Intake and Tumor Cell Homeostasis Drive Early Epithelial Tumorigenesis: A Potential Modelization of Early Prostate Tumorigenesis.

Vialat M, Baabdaty E, Trousson A, Kocer A, Lobaccaro J, Baron S Cancers (Basel). 2024; 16(11).

PMID: 38893271 PMC: 11172085. DOI: 10.3390/cancers16112153.


References
1.
Green J, Cairns B, Casabonne D, Wright F, Reeves G, Beral V . Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk. Lancet Oncol. 2011; 12(8):785-94. PMC: 3148429. DOI: 10.1016/S1470-2045(11)70154-1. View

2.
Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A . Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer. 2010; 46(17):3040-52. DOI: 10.1016/j.ejca.2010.09.013. View

3.
Smith G, Shipley M, Marmot M, Rose G . Plasma cholesterol concentration and mortality. The Whitehall Study. JAMA. 1992; 267(1):70-6. View

4.
Mondul A, Weinstein S, Virtamo J, Albanes D . Serum total and HDL cholesterol and risk of prostate cancer. Cancer Causes Control. 2011; 22(11):1545-52. PMC: 3500884. DOI: 10.1007/s10552-011-9831-7. View

5.
Platz E, Till C, Goodman P, Parnes H, Figg W, Albanes D . Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2009; 18(11):2807-13. PMC: 2877916. DOI: 10.1158/1055-9965.EPI-09-0472. View